Nkarta Inc (NKTX)

$3.28 +0.10 (3.14%)
Market Cap 226.71M
Revenue (ttm) 0.00
Net Income (ttm) -104.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 500,800
Avg Vol 831,616
Day's Range N/A - N/A
Shares Out 71.29M
Stochastic %K 90%
Beta 0.88
Analysts Strong Sell
Price Target $11.60

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic...

Industry: Biotechnology
Sector: Healthcare
Phone: 925 407 1049
Address:
1150 Veterans Boulevard, South San Francisco, United States
BillionerOfKing
BillionerOfKing May. 5 at 3:40 PM
$NKTX Current Stock Price: $3.01 Contracts to trade: $2.5 NKTX May 15 2026 Call Entry: $0.50 Exit: $0.94 ROI: 88% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
purplesniper
purplesniper May. 4 at 8:57 PM
$NKTX
0 · Reply
belugatrade
belugatrade May. 2 at 12:36 AM
$NKTX this pull back is gift.
0 · Reply
nightstocker15
nightstocker15 May. 1 at 7:48 PM
$CUE monster day! Keep an 👁️ on $NKTX starting to make a move higher! Could go kaboom again 💪🎉🔥
0 · Reply
nightstocker15
nightstocker15 May. 1 at 7:38 PM
$NKTX fight fight fight!!!
0 · Reply
nightstocker15
nightstocker15 Apr. 30 at 6:30 PM
$NKTX 👋 that ask!
0 · Reply
purplesniper
purplesniper Apr. 30 at 4:51 PM
$NKTX
0 · Reply
Lukey63
Lukey63 Apr. 29 at 2:42 PM
$NKTX No buyers for this, volume non-existent, back to where it was before the “good news”. F-ing stupid.
1 · Reply
Lukey63
Lukey63 Apr. 29 at 1:43 PM
$NKTX WTF!? Down almost a buck in 6 days! This is retarded.
0 · Reply
MMM_invest
MMM_invest Apr. 28 at 2:32 PM
$NKTX Manipulated! Undervalued!
0 · Reply
Latest News on NKTX
Nkarta reports Q1 EPS (37c), consensus (37c)

2026-05-12T22:15:15.000Z - 13 hours ago

Nkarta reports Q1 EPS (37c), consensus (37c)

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

May 12, 2026, 4:01 PM EDT - 16 hours ago

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

Nkarta announces agreement with FDA on changes to Ntrust-1, Ntrust-2 trials

2026-04-15T20:05:13.000Z - 27 days ago

Nkarta announces agreement with FDA on changes to Ntrust-1, Ntrust-2 trials

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

Apr 15, 2026, 4:01 PM EDT - 27 days ago

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

Nkarta Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 3:45 PM EDT - 27 days ago

Nkarta Transcript: 25th Annual Needham Virtual Healthcare Conference

Nkarta to Participate in Needham Virtual Healthcare Conference

Apr 9, 2026, 7:00 AM EDT - 4 weeks ago

Nkarta to Participate in Needham Virtual Healthcare Conference

Nkarta price target lowered to $12 from $14 at Mizuho

2026-03-31T11:08:50.000Z - 6 weeks ago

Nkarta price target lowered to $12 from $14 at Mizuho

Nkarta price target raised to $11 from $10 at Needham

2026-03-26T11:51:19.000Z - 6 weeks ago

Nkarta price target raised to $11 from $10 at Needham

Nkarta files $350M mixed securities shelf

2026-03-25T21:25:16.000Z - 6 weeks ago

Nkarta files $350M mixed securities shelf

Nkarta reports Q4 EPS (37c), consensus (29c)

2026-03-25T20:05:15.000Z - 6 weeks ago

Nkarta reports Q4 EPS (37c), consensus (29c)

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

Mar 25, 2026, 4:01 PM EDT - 6 weeks ago

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

Nkarta Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 10:40 AM EDT - 2 months ago

Nkarta Transcript: Leerink Global Healthcare Conference 2026

Nkarta Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 2 months ago

Nkarta Transcript: TD Cowen 46th Annual Health Care Conference

Nkarta to Participate in March Investor Conferences

Feb 27, 2026, 8:00 AM EST - 2 months ago

Nkarta to Participate in March Investor Conferences

Nkarta Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 10:50 AM EST - 5 months ago

Nkarta Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nkarta to Participate in Evercore Healthcare Conference

Dec 2, 2025, 7:09 AM EST - 5 months ago

Nkarta to Participate in Evercore Healthcare Conference

Nkarta Transcript: TD Cowen Immunology and Inflammation Summit

Nov 13, 2025, 5:00 PM EST - 6 months ago

Nkarta Transcript: TD Cowen Immunology and Inflammation Summit

Nkarta Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 10:40 AM EST - 6 months ago

Nkarta Transcript: Stifel 2025 Healthcare Conference

Nkarta price target lowered to $11 from $12 at Stifel

2025-11-11T12:45:27.000Z - 6 months ago

Nkarta price target lowered to $11 from $12 at Stifel

Nkarta reports Q3 EPS (29c), consensus (30c)

2025-11-10T21:05:10.000Z - 6 months ago

Nkarta reports Q3 EPS (29c), consensus (30c)

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nov 10, 2025, 4:01 PM EST - 6 months ago

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

Nkarta to Participate in November Investor Conferences

Oct 30, 2025, 1:14 PM EDT - 6 months ago

Nkarta to Participate in November Investor Conferences

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

Oct 22, 2025, 10:07 AM EDT - 7 months ago

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

Nkarta Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 8:30 AM EDT - 8 months ago

Nkarta Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Nkarta to Participate in a September Investor Conference

Sep 2, 2025, 8:01 AM EDT - 9 months ago

Nkarta to Participate in a September Investor Conference

Nkarta price target lowered to $12 from $14 at Stifel

2025-08-14T11:21:16.000Z - 9 months ago

Nkarta price target lowered to $12 from $14 at Stifel

Nkarta reports Q2 EPS (31c), consensus (35c)

2025-08-12T20:13:01.000Z - 9 months ago

Nkarta reports Q2 EPS (31c), consensus (35c)

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 12, 2025, 4:01 PM EDT - 9 months ago

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Nkarta Transcript: H.C. Wainwright “HCW@Home” Series

Jul 30, 2025, 11:00 AM EDT - 10 months ago

Nkarta Transcript: H.C. Wainwright “HCW@Home” Series

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Jul 23, 2025, 8:01 AM EDT - 10 months ago

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Nkarta price target lowered to $14 from $16 at Mizuho

2025-06-10T10:55:13.000Z - 1 year ago

Nkarta price target lowered to $14 from $16 at Mizuho

Nkarta appoints Shawn Rose as CMO, head of R&D

2025-06-06T13:00:35.000Z - 1 year ago

Nkarta appoints Shawn Rose as CMO, head of R&D

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

Jun 6, 2025, 8:52 AM EDT - 1 year ago

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

Nkarta downgraded to Market Perform from Outperform at William Blair

2025-05-15T08:51:43.000Z - 1 year ago

Nkarta downgraded to Market Perform from Outperform at William Blair

Nkarta reports Q1 EPS (43c), consensus (45c)

2025-05-14T20:15:15.000Z - 1 year ago

Nkarta reports Q1 EPS (43c), consensus (45c)

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 14, 2025, 4:01 PM EDT - 1 year ago

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Nkarta Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 11:00 AM EDT - 1 year ago

Nkarta Transcript: 24th Annual Needham Virtual Healthcare Conference

Nkarta to Participate in an April Investor Conference

Apr 1, 2025, 8:01 AM EDT - 1 year ago

Nkarta to Participate in an April Investor Conference

Nkarta price target lowered to $14 from $15 at Stifel

2025-03-27T10:26:21.000Z - 1 year ago

Nkarta price target lowered to $14 from $15 at Stifel

Nkarta announces restructuring and workforce reduction of 34%

2025-03-26T20:16:10.000Z - 1 year ago

Nkarta announces restructuring and workforce reduction of 34%

Nkarta reports Q4 EPS (35c), consensus (40c)

2025-03-26T20:10:42.000Z - 1 year ago

Nkarta reports Q4 EPS (35c), consensus (40c)

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 26, 2025, 4:01 PM EDT - 1 year ago

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Nkarta Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 3:00 PM EDT - 1 year ago

Nkarta Transcript: Leerink Global Healthcare Conference 2025

Nkarta Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 3:10 PM EST - 1 year ago

Nkarta Transcript: TD Cowen 45th Annual Healthcare Conference

Unusually active option classes on open January 7th

2025-01-07T14:40:31.000Z - 1 year ago

Unusually active option classes on open January 7th

CRNC ENVX GETY NOK NVAX PACB PLUG

Nkarta’s Ntrust-2 trial of NKX019 in myasthenia gravis begins enrollment

2024-12-05T11:15:18.000Z - 1 year ago

Nkarta’s Ntrust-2 trial of NKX019 in myasthenia gravis begins enrollment

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Dec 5, 2024, 6:01 AM EST - 1 year ago

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Nkarta Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 4, 2024, 2:10 PM EST - 1 year ago

Nkarta Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nkarta to Participate in an Upcoming Investor Conference

Nov 26, 2024, 7:02 AM EST - 1 year ago

Nkarta to Participate in an Upcoming Investor Conference

Nkarta Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 10:55 AM EST - 1 year ago

Nkarta Transcript: Stifel 2024 Healthcare Conference

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Nov 7, 2024, 4:02 PM EST - 1 year ago

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Nkarta Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 12:30 PM EDT - 1 year ago

Nkarta Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Nkarta to Participate in Upcoming Investor Conference

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conference

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 9:03 PM EDT - 1 year ago

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Jul 24, 2024, 6:00 AM EDT - 1 year ago

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Jul 16, 2024, 6:01 AM EDT - 1 year ago

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Jun 27, 2024, 6:00 AM EDT - 2 years ago

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

Jun 13, 2024, 4:01 PM EDT - 2 years ago

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

May 9, 2024, 4:01 PM EDT - 2 years ago

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Nkarta Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 9, 2024, 1:30 PM EDT - 2 years ago

Nkarta Transcript: 23rd Annual Needham Virtual Healthcare Conference

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 5, 2024, 3:35 PM EDT - 2 years ago

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Nkarta to Participate in Upcoming Investor Conferences

Apr 3, 2024, 4:02 PM EDT - 2 years ago

Nkarta to Participate in Upcoming Investor Conferences

Nkarta Transcript: H.C. Wainwright 2ND Annual Cell Therapy Virtual Conference

Mar 26, 2024, 2:00 PM EDT - 2 years ago

Nkarta Transcript: H.C. Wainwright 2ND Annual Cell Therapy Virtual Conference

Nkarta Announces Pricing of $240 Million Underwritten Offering

Mar 25, 2024, 6:30 AM EDT - 2 years ago

Nkarta Announces Pricing of $240 Million Underwritten Offering

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Mar 21, 2024, 4:01 PM EDT - 2 years ago

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Nkarta Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 11, 2024, 12:00 PM EDT - 2 years ago

Nkarta Transcript: Leerink Partners Global Biopharma Conference 2024

Nkarta Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 6, 2024, 9:10 AM EST - 2 years ago

Nkarta Transcript: TD Cowen 44th Annual Health Care Conference 2024

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Dec 9, 2023, 8:31 PM EST - 2 years ago

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nkarta Transcript: 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 12:30 PM EST - 2 years ago

Nkarta Transcript: 6th Annual Evercore ISI HealthCONx Conference

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nov 9, 2023, 4:02 PM EST - 2 years ago

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nkarta to Participate at Upcoming Investor Conferences

Nov 7, 2023, 8:02 AM EST - 2 years ago

Nkarta to Participate at Upcoming Investor Conferences

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Oct 17, 2023, 11:47 AM EDT - 2 years ago

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Nkarta Transcript: FDA Announcement

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Nkarta Transcript: FDA Announcement

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Oct 17, 2023, 7:01 AM EDT - 2 years ago

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Oct 16, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Aug 10, 2023, 7:01 AM EDT - 2 years ago

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Nkarta to Participate at Upcoming Investor Conference

Aug 3, 2023, 8:02 AM EDT - 3 years ago

Nkarta to Participate at Upcoming Investor Conference

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

Jul 5, 2023, 4:02 PM EDT - 3 years ago

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

Nkarta Transcript: Study Update

Jun 27, 2023, 8:00 AM EDT - 3 years ago

Nkarta Transcript: Study Update

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jun 27, 2023, 7:01 AM EDT - 3 years ago

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

Jun 26, 2023, 4:01 PM EDT - 3 years ago

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Jun 10, 2023, 10:47 AM EDT - 3 years ago

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

May 11, 2023, 4:02 PM EDT - 3 years ago

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

May 11, 2023, 4:01 PM EDT - 3 years ago

Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

Apr 26, 2023, 7:00 AM EDT - 3 years ago

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

TNYA

Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting

Apr 17, 2023, 5:01 PM EDT - 3 years ago

Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting

Nkarta Announces Departure of Chief Financial & Business Officer

Mar 30, 2023, 4:01 PM EDT - 3 years ago

Nkarta Announces Departure of Chief Financial & Business Officer

BillionerOfKing
BillionerOfKing May. 5 at 3:40 PM
$NKTX Current Stock Price: $3.01 Contracts to trade: $2.5 NKTX May 15 2026 Call Entry: $0.50 Exit: $0.94 ROI: 88% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
purplesniper
purplesniper May. 4 at 8:57 PM
$NKTX
0 · Reply
belugatrade
belugatrade May. 2 at 12:36 AM
$NKTX this pull back is gift.
0 · Reply
nightstocker15
nightstocker15 May. 1 at 7:48 PM
$CUE monster day! Keep an 👁️ on $NKTX starting to make a move higher! Could go kaboom again 💪🎉🔥
0 · Reply
nightstocker15
nightstocker15 May. 1 at 7:38 PM
$NKTX fight fight fight!!!
0 · Reply
nightstocker15
nightstocker15 Apr. 30 at 6:30 PM
$NKTX 👋 that ask!
0 · Reply
purplesniper
purplesniper Apr. 30 at 4:51 PM
$NKTX
0 · Reply
Lukey63
Lukey63 Apr. 29 at 2:42 PM
$NKTX No buyers for this, volume non-existent, back to where it was before the “good news”. F-ing stupid.
1 · Reply
Lukey63
Lukey63 Apr. 29 at 1:43 PM
$NKTX WTF!? Down almost a buck in 6 days! This is retarded.
0 · Reply
MMM_invest
MMM_invest Apr. 28 at 2:32 PM
$NKTX Manipulated! Undervalued!
0 · Reply
nightstocker15
nightstocker15 Apr. 27 at 7:53 PM
$NKTX data expected mid May! Taking advantage of the pull back 💪🔥
0 · Reply
Lamatozore
Lamatozore Apr. 26 at 3:37 PM
$NKTX back to 3.15 monday
0 · Reply
Lukey63
Lukey63 Apr. 24 at 7:23 PM
$NKTX This stock is flaccid. Meanwhile certain tech stocks with modest sales and no earnings go to the moon. Value is out.
0 · Reply
aquira
aquira Apr. 23 at 2:24 PM
$NKTX looks like we'll be gping back to 2.0-2.10. Fuck this sheet
2 · Reply
theBigDollarski
theBigDollarski Apr. 22 at 7:37 PM
$NKTX this should rationally be trading around 6 compared to $ARTV and $KYTX.
0 · Reply
aquira
aquira Apr. 21 at 7:59 PM
$NKTX from 52-week high of 3.65 to 3.30 in 30 minutes. Fooken hell. Why is there a power hour dumping?
1 · Reply
ontariomark
ontariomark Apr. 21 at 7:35 PM
$NKTX 🚀 FDA approval for outpatient dosing on NKX019 is a total game-changer for scaling their autoimmune tech. Massive upside toward that $12 analyst target and data catalysts are right around the corner. Ready for the breakout!
0 · Reply
ontariomark
ontariomark Apr. 21 at 7:10 PM
$NKTX getting spicy!! 🔥
0 · Reply
StockScanners
StockScanners Apr. 21 at 3:33 AM
$NKTX reached 3.53
0 · Reply
BiotechValues
BiotechValues Apr. 20 at 2:12 PM
$NKTX data abstract should be out mid-May (same time as ARTV RA abstract). Notable they got an oral presentation IMO. No formal press release yet about their attendance/oral slot, so nice to see this in advance of the crowd.
0 · Reply
Lukey63
Lukey63 Apr. 19 at 11:57 PM
$NKTX Tomorrow will be interesting. Will this continue to run or will the Iran conflict derail the rally? On a macro basic perhaps but specific names should not be impacted.
0 · Reply
theroverriver
theroverriver Apr. 19 at 3:39 AM
$NKTX she's been choppy but she's running now HODL with 10k shares
0 · Reply